{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:26:34Z","timestamp":1776399994704,"version":"3.51.2"},"reference-count":58,"publisher":"Georg Thieme Verlag KG","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973473"],"award-info":[{"award-number":["81973473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2023J01577"],"award-info":[{"award-number":["2023J01577"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"crossref","award":["2024CXA021"],"award-info":[{"award-number":["2024CXA021"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2021Y9152"],"award-info":[{"award-number":["2021Y9152"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of angiogenesis inhibitors has expanded therapeutic options for tumors but poses challenges due to bleeding risks, especially in patients requiring anticoagulation therapy for cancer-associated hypercoagulability.<\/jats:p>\n                  <jats:p>This study aimed to evaluate whether combining anticoagulants with angiogenesis inhibitors increases bleeding risk in cancer patients.<\/jats:p>\n                  <jats:p>A network meta-analysis was conducted based on PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials to compare bleeding risks with angiogenesis inhibitors alone versus their combination with anticoagulants. Furthermore, a real-world cohort of 645 patients receiving antiangiogenic therapies between January 2010 and June 2024 was studied. Patients were separated into two groups according to whether they were receiving concomitant anticoagulants. The primary outcome was all-grade bleeding events.<\/jats:p>\n                  <jats:p>Of 2,644 patients from six studies included in network meta-analysis, all-grade bleeding events were found in 614 (23.2%) patients. The addition of anticoagulation to either high-dose bevacizumab (10 or 15\u2009mg\/kg) (OR 4.95, 95% CI: 2.68\u20139.42) or antiangiogenic tyrosine kinase inhibitors (OR 2.2, 95% CI: 1.08\u20134.44) significantly increased bleeding risk compared with antiangiogenic monotherapy, except for low-dose bevacizumab (5 or 7.5\u2009mg\/kg). In the cohort study, 163 patients matched in each group after propensity score matching weighting. Over a median follow-up duration of 56 days, there were 28 (17.2%) all-grade bleeding events during concurrent treatment and 16 (9.8%) all-grade bleeding events reported during antiangiogenic monotherapy.<\/jats:p>\n                  <jats:p>Adding anticoagulation to high-dose bevacizumab or antiangiogenic TKIs might increase bleeding risk compared with monotherapy. Conversely, anticoagulants appeared to be safe in patients receiving low-dose bevacizumab.<\/jats:p>","DOI":"10.1055\/a-2740-1655","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:55:53Z","timestamp":1762559753000},"source":"Crossref","is-referenced-by-count":1,"title":["Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?"],"prefix":"10.1055","author":[{"given":"Qixin","family":"Chen","sequence":"first","affiliation":[{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongni","family":"Nian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuzhou Second Hospital, Fuzhou, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4787-2506","authenticated-orcid":false,"given":"Xiongwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"N Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"N Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1200\/JCO.22.02760","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"41","author":"L B Saltz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"28","key":"ref6","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"H S Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"A Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"26","key":"ref8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"R A Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"G C Jayson","year":"2016","journal-title":"Lancet"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12565-009-0026-1","article-title":"Regulation of endothelial cell differentiation and arterial specification by VEGF and Notch signaling","volume":"84","author":"M Hirashima","year":"2009","journal-title":"Anat Sci Int"},{"issue":"22","key":"ref11","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1073\/pnas.0802857105","article-title":"Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7","volume":"105","author":"S Wang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"B C Kuenen","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"P Prandoni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"S 01","key":"ref14","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6605599","article-title":"Epidemiology and pathophysiology of cancer-associated thrombosis","volume":"102","author":"S Noble","year":"2010","journal-title":"Br J Cancer"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"N B Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"J F Timp","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref17","first-page":"73","article-title":"Cancer in the elderly","volume":"2","author":"D Cinar","year":"2015","journal-title":"North Clin Istanb"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12170-016-0491-8","article-title":"Multimorbidity in older patients with cardiovascular disease","volume":"10","author":"S M Dunlay","year":"2016","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"A R Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"A Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"G van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"G Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"A A Veroniki","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"J P Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"7414","key":"ref26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"J P Higgins","year":"2003","journal-title":"BMJ"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejphar.2016.10.039","article-title":"Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions","volume":"793","author":"Z Lin","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"B Xiao","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1215\/15228517-2008-009","article-title":"Safety of anticoagulation use and bevacizumab in patients with glioma","volume":"10","author":"P L Nghiemphu","year":"2008","journal-title":"Neuro-oncol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lungcan.2011.11.020","article-title":"MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC","volume":"76","author":"E Dansin","year":"2012","journal-title":"Lung Cancer"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"M Reck","year":"2009","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-011-0642-1","article-title":"Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients","volume":"106","author":"A D Norden","year":"2012","journal-title":"J Neurooncol"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"H M Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mdt292","article-title":"Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials","volume":"24","author":"W X Qi","year":"2013","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.critrevonc.2017.10.014","article-title":"Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma","volume":"120","author":"M Crist","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.33337","article-title":"Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin","volume":"127","author":"S H Patel","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"e2061","DOI":"10.1002\/onco.13897","article-title":"Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation","volume":"26","author":"A Sivakumar","year":"2021","journal-title":"Oncologist"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"T F Wang","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","article-title":"Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I\/II pharmacokinetic interaction study","volume":"68","author":"K T Flaherty","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor","volume":"42","author":"Z Hussein","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"W Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/bcp.15785","article-title":"Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis","volume":"89","author":"L Van der Linden","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST Guidelines 2012-2021","volume":"166","author":"S M Stevens","year":"2024","journal-title":"Chest"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"ref48","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1164\/rccm.201909-1782RR","article-title":"Prevention and treatment of thromboembolic events in patients with cancer: advances and challenges","volume":"202","author":"M H Denault","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.mayocp.2019.05.035","article-title":"Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis","volume":"94","author":"H E Fuentes","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions","volume":"20","author":"D Q Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"D Q Huang","year":"2022","journal-title":"Cell Metab"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Q M Anstee","year":"2022","journal-title":"J Hepatol"},{"issue":"09","key":"ref54","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"D Q Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"V Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"20","key":"ref56","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref57","first-page":"2919","article-title":"Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis","volume":"30","author":"C Frere","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"ref58","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.2019001605","article-title":"How I assess and manage the risk of bleeding in patients treated for venous thromboembolism","volume":"135","author":"F A Klok","year":"2020","journal-title":"Blood"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2740-1655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:10:56Z","timestamp":1764375056000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2740-1655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1055\/a-2740-1655","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,7]]},"published":{"date-parts":[[2025,11,7]]}}}